

# Transfemoral Mitral Valve Repair System Wins CRT 2022 Best Innovation Competition

In the light of this award, NeoChord wants to thank all the experts and hospital team members supporting us during the NeoChord NeXuS first-in-human experience.

Our special thanks goes to:

Azeem Latib, MD; Edwin Ho, MD (*Montefiore Medical Center New York*)

Thomas Modine, MD; Lionel Leroux, MD (*CHU de Bordeaux*)

Stephan von Bardeleben, MD; Felix Kreidel, MD (*University Hospital of Mainz*)

Posted: 02/28/2022

Author: Jason Wermers, CRTonline.org



A device designed for transfemoral transcatheter mitral valve repair won the CRT Best Innovation Competition on Monday afternoon.

The NeoChord NeXuS System was presented by Azeem Latib, MD, of Montefiore Medical Center, New York. CRT 2022 Course Chairman Ron Waksman, MD, announced and presented awards to the top three entries in the competition.

Dr. Latib presented results of a first-in-man experience with the valve. The patient was a 55-year-old male with a history of coronary artery disease, atrial fibrillation and prostate cancer. He presented with severe mitral regurgitation and New York Heart Association class 3 heart failure.

Thirty days after the device was implanted, echocardiography showed that the NeXuS was “mimicking the native construction of the papillary muscle and physiological function of the mitral valve,” Dr. Latib said.

He added that he would recommend that clinicians have experience using the other mitral clip devices before trying to use the NeoChord NeXuS. He said that placing the NeXuS is similar to other mitral clips, but the added step is that the NeXuS gets anchored to the papillary muscles, providing extra stability.

At 3 months in the first patient to receive the NeXuS, the results were still good and durable. Dr. Latib said the device provides for a “safe and elegant” transcatheter mitral valve repair, it leaves a small footprint that preserves the physiological leaflet function and allows for future procedures, including future mitral valve surgery, if needed. He added that it could be used in younger patients.

Finishing second in the competition was the AccuCinch Ventricular Restoration System, which is designed to treat heart failure with reduced ejection fraction, presented by Jason Foerst, MD, of Carilion Clinic, Salem, Virginia. Third place went to Pressure-Controlled Coronary Sinus Occlusion (PiCSO), a device and procedure designed to improve coronary microcirculation and reduce infarct size in patients with ST-elevation myocardial infarction, presented by C. Michael Gibson, MD, of Beth Israel Deaconess Medical Center, Boston.

The competition included 11 finalists. Dr. Waksman said that was because the entries were very strong this year, making it difficult to cut it down to 10.

To those that did not make the top three, Dr. Waksman said the judges told him that the quality was so high, more than three easily could have made it.

“Continue to innovate, continue to submit to our meeting, to other meetings, and continue to move your technology,” he said.

<https://www.crtonline.org/news-detail/transfemoral-mitral-valve-repair-system-wins-crt-2>

The investigational NeoChord NeXuS Transcatheter Mitral Chordal Repair device is designed to restore function in patients with severe symptomatic primary mitral regurgitation (MR), a disease where blood leaks backwards within the heart, due to ruptured native chords and the mitral valve's inability to close properly. The NeoChord NeXuS Transcatheter Mitral Chordal Repair device is unique from other mitral valve repair technologies in maintaining a natural physiologic functionality of the mitral valve. It is deployed through the vein using a transfemoral delivery catheter, navigated transeptally to the diseased native mitral valve. Due to minimal hardware used and the proven leaflet connection, NeoChord NeXuS preserves options for patients who may need re-intervention in the future.